Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate zanzalintinib showing potential to offset future revenue losses.

Anticancer Peptide Market Offers US$ 18 Billion Opportunity Says Kuick Research. Delhi, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The ...

Exelixis (EXEL) stock in focus as U.S. FDA leaves out an AdCom in its review of the firm's label expansion for cancer therapy ...

Exelixis said it was notified by the Food and Drug Administration that its treatment for advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic will not be discussed at a meeting.

Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals for ...

Award follows extensive pre-clinical, single agent activity data generated by Prof. Colleen Nelson's lab at QUT in 'Aggressive Variant' prostate ca ...

Life without a pancreas involves treatments to replace organ function. Learn how different surgical techniques affect overall ...

Irrfan Khan's final film appearance was in Angrezi Medium, directed by Homi Adajania, which was released in March 2020.

This new funding positions NRMA Insurance as the first corporate partner to support a McGrath Cancer Care Nurse since the ...

After surviving colon cancer, I reflect on how the lessons from my journey transformed my life and guide me to embrace its ...

Perspective has delivered initial clinical data for two new potential medicines based on its next generation targeted radiopharmaceutical technology platform, and is poised to do more in the next 18 ...

AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Neuroendocrine Tumors.